Key result
Oral cilostamide suppresses intimal hyperplasia ~83% in a rat model by inhibiting VSMC proliferation.
Why the study?
The effects of cilostamide, a PDE3 selective inhibitor, on vascular intimal hyperplasia were not fully evaluated in rat balloon injury models.
Does cilostamide reduce intimal hyperplasia in rat balloon injury models?
Population
Rats with single and double common carotid artery balloon injuries and cultured vascular smooth muscle cells
Comparison
Oral cilostamide administration vs no treatment
Design
Preclinical experimental study with in vivo and in vitro components
Follow-up
2 weeks
Authors
Loading...
Cilostamide does not support clinical use against restenosis; extends preclinical evidence for PDE3 inhibition in repeated vascular injury models.
Does cilostamide reduce intimal hyperplasia in rat balloon injury models?
Effect estimate: 83% inhibition
p-value: p=<0.05
Cilostamide suppresses intimal hyperplasia in rat balloon injury models by inhibiting VSMC proliferation, suggesting potential utility in preventing restenosis after angioplasty.
Inoué et al. (2000) studied Vascular intimal hyperplasia. Cilostamide was evaluated on Intimal hyperplasia (intima/media ratio) (83% inhibition, p=<0.05). Oral administration of cilostamide for 2 weeks significantly suppressed intimal hyperplasia in a rat double-injury model by up to 83% (P<0.05), likely by inhibiting vascular smooth muscle cell proliferation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: